# Kangfeng Biotechnology (Shanghai) Co.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/kangfeng-biotechnology-shanghai-co

- Industry: Medical Devices & Equipment
- Headquarters: Shanghai, China
- Website: www.cryofocus.com
- Total disclosed funding: $1.1B
- Latest round: Series B (Feb 22, 2021)
- Investors on record: 9

## About

Established in 2013 and based in Shanghai, China, Kangfeng Biotechnology (Shanghai) Co., Ltd. operates as a cryo-medical technology platform that focuses on vascular intervention and trans-natural lumen field. The core research team has more than ten years of experience in R&D and practical engineering application of medical device. In 2018, the company raised USD 1.078 billion in series B funding led by GL Ventures. In December 2022, the company was listed on the Hongkong stock exchange and its stock code is 06922. In 2022, its products - bladder tumor cryoablation system and endoscopic anastomosis clips obtain registration certificate.

The company provides cryotherapy solutions. Its products are divided into cryotherapy system and non-cryotherapy products. Cryotherapy system includes atrial fibrillation, hypertension and bladder cancer, etc. Non-cryotherapy products includes new endoscopic anastomotic clamp and anti-gastroesophageal reflux system.

## Funding rounds

- Series B, Feb 22, 2021, $1.1B — Proxima Ventures, Qingdao Guoxin Venture, FutureX Capital, GL Ventures, Ningbo Tongshang Fund, Qianhai Fu Rong (Shenzhen) Investment Management
- Series A, Dec 10, 2018 — China Galaxy Investment Management, Wisdomont Capital, Proxima Ventures
- Series A, Feb 1, 2018 — YuanBio Venture

## Investors

- YuanBio Venture (https://capitalatlas.ai/funds/yuanbio-venture) — Series A
- China Galaxy Investment Management (https://capitalatlas.ai/funds/china-galaxy-investment-management) — Series A
- Wisdomont Capital (https://capitalatlas.ai/funds/wisdomont-capital) — Series A
- Proxima Ventures (https://capitalatlas.ai/funds/proxima-ventures) — Series A, Series B
- Qingdao Guoxin Venture — Series B
- FutureX Capital (https://capitalatlas.ai/funds/futurex-capital) — Series B
- GL Ventures (https://capitalatlas.ai/funds/gl-ventures) — Series B
- Ningbo Tongshang Fund (https://capitalatlas.ai/funds/ningbo-tongshang-fund) — Series B
- Qianhai Fu Rong (Shenzhen) Investment Management — Series B